Accelerate Diagnostics Competitors

Accelerate Diagnostics (NASDAQ:AXDX) and Illumina (NASDAQ:ILMN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Volatility and Risk

Accelerate Diagnostics has a beta of 2.35, meaning that its stock price is 135% more volatile than the S&P 500. Comparatively, Illumina has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500.

Profitability

This table compares Accelerate Diagnostics and Illumina's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Accelerate Diagnostics and Illumina's revenue, earnings per share (EPS) and valuation.

Illumina has higher revenue and earnings than Accelerate Diagnostics. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Accelerate Diagnostics and Illumina, as provided by MarketBeat.com.

Accelerate Diagnostics presently has a consensus price target of $17.50, indicating a potential upside of 97.29%. Illumina has a consensus price target of $370.5789, indicating a potential downside of 8.13%. Given Accelerate Diagnostics' stronger consensus rating and higher possible upside, research analysts clearly believe Accelerate Diagnostics is more favorable than Illumina.

Institutional and Insider Ownership

51.8% of Accelerate Diagnostics shares are owned by institutional investors. Comparatively, 90.0% of Illumina shares are owned by institutional investors. 44.4% of Accelerate Diagnostics shares are owned by company insiders. Comparatively, 0.4% of Illumina shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Illumina beats Accelerate Diagnostics on 9 of the 14 factors compared between the two stocks.

Accelerate Diagnostics (NASDAQ:AXDX) and Agilent Technologies (NYSE:A) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, profitability, valuation and dividends.

Profitability

This table compares Accelerate Diagnostics and Agilent Technologies' net margins, return on equity and return on assets.

Insider & Institutional Ownership

51.8% of Accelerate Diagnostics shares are held by institutional investors. 44.4% of Accelerate Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Accelerate Diagnostics and Agilent Technologies' gross revenue, earnings per share (EPS) and valuation.

Agilent Technologies has higher revenue and earnings than Accelerate Diagnostics. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Accelerate Diagnostics and Agilent Technologies, as provided by MarketBeat.com.

Accelerate Diagnostics presently has a consensus price target of $17.50, suggesting a potential upside of 97.29%. Agilent Technologies has a consensus price target of $104.70, suggesting a potential downside of 20.63%. Given Accelerate Diagnostics' higher probable upside, equities analysts clearly believe Accelerate Diagnostics is more favorable than Agilent Technologies.

Volatility & Risk

Accelerate Diagnostics has a beta of 2.35, suggesting that its share price is 135% more volatile than the S&P 500. Comparatively, Agilent Technologies has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500.

Summary

Agilent Technologies beats Accelerate Diagnostics on 9 of the 14 factors compared between the two stocks.

Mettler-Toledo International (NYSE:MTD) and Accelerate Diagnostics (NASDAQ:AXDX) are both computer and technology companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings and target prices for Mettler-Toledo International and Accelerate Diagnostics, as reported by MarketBeat.

Mettler-Toledo International presently has a consensus target price of $971.3750, suggesting a potential downside of 20.54%. Accelerate Diagnostics has a consensus target price of $17.50, suggesting a potential upside of 97.29%. Given Accelerate Diagnostics' stronger consensus rating and higher probable upside, analysts clearly believe Accelerate Diagnostics is more favorable than Mettler-Toledo International.

Volatility & Risk

Mettler-Toledo International has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Accelerate Diagnostics has a beta of 2.35, meaning that its share price is 135% more volatile than the S&P 500.

Profitability

This table compares Mettler-Toledo International and Accelerate Diagnostics' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Mettler-Toledo International and Accelerate Diagnostics' top-line revenue, earnings per share (EPS) and valuation.

Mettler-Toledo International has higher revenue and earnings than Accelerate Diagnostics. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

93.2% of Mettler-Toledo International shares are held by institutional investors. Comparatively, 51.8% of Accelerate Diagnostics shares are held by institutional investors. 3.2% of Mettler-Toledo International shares are held by company insiders. Comparatively, 44.4% of Accelerate Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Mettler-Toledo International beats Accelerate Diagnostics on 8 of the 14 factors compared between the two stocks.

10x Genomics (NASDAQ:TXG) and Accelerate Diagnostics (NASDAQ:AXDX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Valuation and Earnings

This table compares 10x Genomics and Accelerate Diagnostics' gross revenue, earnings per share and valuation.

10x Genomics has higher revenue and earnings than Accelerate Diagnostics. 10x Genomics is trading at a lower price-to-earnings ratio than Accelerate Diagnostics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares 10x Genomics and Accelerate Diagnostics' net margins, return on equity and return on assets.

Volatility & Risk

10x Genomics has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Comparatively, Accelerate Diagnostics has a beta of 2.35, indicating that its stock price is 135% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for 10x Genomics and Accelerate Diagnostics, as provided by MarketBeat.

10x Genomics presently has a consensus price target of $181.4444, indicating a potential downside of 6.78%. Accelerate Diagnostics has a consensus price target of $17.50, indicating a potential upside of 97.29%. Given Accelerate Diagnostics' higher possible upside, analysts plainly believe Accelerate Diagnostics is more favorable than 10x Genomics.

Insider and Institutional Ownership

68.8% of 10x Genomics shares are owned by institutional investors. Comparatively, 51.8% of Accelerate Diagnostics shares are owned by institutional investors. 13.3% of 10x Genomics shares are owned by company insiders. Comparatively, 44.4% of Accelerate Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

10x Genomics beats Accelerate Diagnostics on 9 of the 14 factors compared between the two stocks.

Waters (NYSE:WAT) and Accelerate Diagnostics (NASDAQ:AXDX) are both computer and technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings for Waters and Accelerate Diagnostics, as provided by MarketBeat.com.

Waters presently has a consensus price target of $224.20, indicating a potential downside of 27.00%. Accelerate Diagnostics has a consensus price target of $17.50, indicating a potential upside of 97.29%. Given Accelerate Diagnostics' stronger consensus rating and higher probable upside, analysts clearly believe Accelerate Diagnostics is more favorable than Waters.

Earnings & Valuation

This table compares Waters and Accelerate Diagnostics' top-line revenue, earnings per share and valuation.

Waters has higher revenue and earnings than Accelerate Diagnostics. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Waters has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, Accelerate Diagnostics has a beta of 2.35, indicating that its stock price is 135% more volatile than the S&P 500.

Profitability

This table compares Waters and Accelerate Diagnostics' net margins, return on equity and return on assets.

Insider & Institutional Ownership

91.8% of Waters shares are owned by institutional investors. Comparatively, 51.8% of Accelerate Diagnostics shares are owned by institutional investors. 1.5% of Waters shares are owned by insiders. Comparatively, 44.4% of Accelerate Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Accelerate Diagnostics (NASDAQ:AXDX) and Avantor (NYSE:AVTR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Institutional and Insider Ownership

51.8% of Accelerate Diagnostics shares are held by institutional investors. Comparatively, 84.8% of Avantor shares are held by institutional investors. 44.4% of Accelerate Diagnostics shares are held by company insiders. Comparatively, 1.9% of Avantor shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Accelerate Diagnostics and Avantor's net margins, return on equity and return on assets.

Risk and Volatility

Accelerate Diagnostics has a beta of 2.35, suggesting that its share price is 135% more volatile than the S&P 500. Comparatively, Avantor has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Accelerate Diagnostics and Avantor, as provided by MarketBeat.com.

Accelerate Diagnostics presently has a consensus price target of $17.50, suggesting a potential upside of 97.29%. Avantor has a consensus price target of $29.7941, suggesting a potential downside of 6.10%. Given Accelerate Diagnostics' higher possible upside, analysts clearly believe Accelerate Diagnostics is more favorable than Avantor.

Earnings & Valuation

This table compares Accelerate Diagnostics and Avantor's revenue, earnings per share (EPS) and valuation.

Avantor has higher revenue and earnings than Accelerate Diagnostics. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than Avantor, indicating that it is currently the more affordable of the two stocks.

Summary

Avantor beats Accelerate Diagnostics on 10 of the 14 factors compared between the two stocks.